Stockscreener 앱 받기
23.25
2.92%
-0.70
전일 마감가:
$23.95
열려 있는:
$24
하루 거래량:
571.50K
Relative Volume:
1.45
시가총액:
$465.26M
수익:
$925.00K
순이익/손실:
$-98.64M
주가수익비율:
-4.6323
EPS:
-5.0191
순현금흐름:
$-83.37M
1주 성능:
-11.93%
1개월 성능:
-32.94%
6개월 성능:
-9.29%
1년 성능:
-31.60%
1일 변동 폭
$23.00
$24.27
1주일 범위
$21.05
$27.15
52주 변동 폭
$15.93
$43.66
Neurogene Inc Stock (NGNE) Company Profile
명칭
Neurogene Inc
전화
(877) 237-5020
주소
535 W 24TH STREET, NEW YORK
Compare NGNE vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NGNE
Neurogene Inc
|
23.25 | 465.26M | 925.00K | -98.64M | -83.37M | -5.0191 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-10-08 | 개시 | JP Morgan | Overweight |
| 2026-06-03 | 개시 | Rodman & Renshaw | Buy |
| 2025-06-17 | 개시 | Craig Hallum | Buy |
| 2025-05-16 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-06-27 | 개시 | BMO Capital Markets | Outperform |
| 2024-06-11 | 개시 | Robert W. Baird | Outperform |
| 2024-04-29 | 개시 | Leerink Partners | Outperform |
| 2024-03-21 | 개시 | William Blair | Outperform |
| 2024-01-08 | 개시 | H.C. Wainwright | Buy |
| 2024-01-05 | 개시 | Stifel | Buy |
| 2024-01-04 | 개시 | TD Cowen | Outperform |
모두보기
Neurogene Inc 주식(NGNE)의 최신 뉴스
Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects? - Zacks Investment Research
Prudential reports a passive Neurogene (NGNE) stake spanning more than 2 million shares. - Stock Titan
A passive investor reports 2.23 million shares of Neurogene (NGNE). - Stock Titan
Five new hires’ options vest over four years, if they stay - Stock Titan
Form 4 Neurogene Inc For: 2 October By Investing.com - Investing.com South Africa
Form 4 Neurogene Inc For: 2 October By Investing.com - Investing.com Canada
Form 4 Neurogene Inc For: 2 October By Investing.com - Investing.com UK
Neurogene Inc. (NGNE) Stock Price & News - Syfe
Neurogene (Nasdaq:NGNE)Stock Analysis - Simply Wall Street
A live webcast will feature Neurogene on Sept. 15. - Stock Titan
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Certain Stock Options of Neurogene Inc. are subject to a Lock-Up Agreement Ending on 31-AUG-2026. - marketscreener.com
Certain Pre-Funded Warrants of Neurogene Inc. are subject to a Lock-Up Agreement Ending on 31-AUG-2026. - marketscreener.com
Balyasny Asset Management L.P. Expands Neurogene Inc (NGNE) Stak - GuruFocus
Neurogene (NGNE) Watch: Posts a 4.45% Loss to $37.67 in the Current Update; Trading Range: Support at $35.79 and Resistance at $39.55 Frame the Range on the DayMarket Leader Picks - vinanet.vn
Neurogene (NGNE) Latest Quarter: Profit Per Share Falls Below Its Benchmark in Latest Trading; Market Response: Shares Finish 10.54% Higher in the Current UpdateLong-Term Guidance - dars.gov.et
Neurogene (NGNE) Latest Quarter: Profit Per Share Falls Below Its Benchmark in Latest Trading; Market Response: Shares Finish 10.54% Higher in the Current UpdateFull Year Guidance - vinanet.vn
Neurogene (NGNE) Results at a Glance: The Bottom-Line Figure Trails Its Comparison in the Latest Reading; Market Response: Shares Rise 10.54% for the Current SessionGuidance Upgrade Report - vinanet.vn
Neurogene gearing up to apply for approval of Rett gene therapy - Rett Syndrome News
Neurogene (NGNE) Results at a Glance: The Bottom-Line Figure Trails Its Comparison in the Latest Reading; Market Response: Shares Rise 10.54% for the Current SessionBalance Sheet Strength - dars.gov.et
NGNE Q1 2026 Earnings: Narrow EPS Miss Masks Positive Investor SentimentEarnings Forecast Report - vinanet.vn
Neurogene (NGNE) Gains 1.43% to $36.14: Key Resistance at $37.95 in FocusMoney Flow Index - vinanet.vn
Neurogene Inc. $NGNE Shares Bought by Renaissance Technologies LLC - MarketBeat
Neurogene (NGNE) Gains 1.43% to $36.14: Key Resistance at $37.95 in FocusVolume Spike Alerts - siam.in
Neurogene Inc. (NGNE): Redmile Group and Jeremy Green disclose 9.9% stake - Stock Titan
Neurogene (NGNE) filers disclose 714,885-share Trails Edge stake at 4.5% - Stock Titan
Q3 Earnings Forecast for Neurogene Issued By HC Wainwright - marketbeat.com
Balyasny Asset Management (NGNE) discloses 5.18% Neurogene stake via Atlas fund - Stock Titan
Stifel Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $46 - Moomoo
H.C. Wainwright Maintains Neurogene(NGNE.US) With Buy Rating, Cuts Target Price to $65 - Moomoo
A Quick Look at Today's Ratings for Neurogene(NGNE.US), With a Forecast Between $63 to $166 - Moomoo
Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Cardiff Oncology (CRDF) - The Globe and Mail
Neurogene (NASDAQ:NGNE) Given New $166.00 Price Target at Canaccord Genuity Group - MarketBeat
Neurogene Maintained at Buy as Rett Program Progress and Strong Cash Runway Offset Price Target Trim from $180 to $166 - TipRanks
Neurogene (NGNE) Dips 2% to $35.8: Gene Therapy Developer Holds Above Key SupportSector Neutral Pair - Vinanet
Neurogene stock price target lowered to $65 by H.C. Wainwright - Investing.com
Neurogene stock price target lowered to $65 by H.C. Wainwright - Investing.com Australia
Canaccord lowers Neurogene stock price target on valuation review By Investing.com - Investing.com Nigeria
HC Wainwright Issues Pessimistic Forecast for Neurogene (NASDAQ:NGNE) Stock Price - marketbeat.com
Canaccord lowers Neurogene stock price target on valuation review By Investing.com - Investing.com South Africa
Neurogene stock price target lowered to $65 by H.C. Wainwright - Investing.com India
Neurogene stock price target lowered to $65 by H.C. Wainwright - Investing.com
Canaccord lowers Neurogene stock price target on valuation review - Investing.com
William Blair Maintains Neurogene(NGNE.US) With Buy Rating - Moomoo
LifeSci Capital Maintains Neurogene(NGNE.US) With Buy Rating, Cuts Target Price to $63 - Moomoo
Canaccord lowers Neurogene stock price target on valuation review By Investing.com - Investing.com Canada
Canaccord lowers Neurogene stock price target on valuation review By Investing.com - Investing.com India
TD Cowen Maintains Neurogene(NGNE.US) With Buy Rating - Moomoo
Neurogene Inc. Stock 12‑Month Price Target Cut to $79.75, Implies 118% Upside - TradingView
Neurogene Inc (NGNE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Neurogene Inc 주식 (NGNE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Cvijic Christine Mikail | President and CFO |
Jul 07 '26 |
Sale |
36.13 |
4,200 |
151,763 |
84,040 |
| Cvijic Christine Mikail | President and CFO |
Jul 06 '26 |
Sale |
36.02 |
600 |
21,613 |
88,240 |
| Cvijic Christine Mikail | President and CFO |
Jul 02 '26 |
Sale |
34.82 |
4,061 |
141,417 |
88,840 |
| Cvijic Christine Mikail | President and CFO |
Jul 01 '26 |
Sale |
34.06 |
739 |
25,170 |
92,901 |
| Christine Cvijic | Officer |
May 06 '26 |
Proposed Sale |
28.94 |
14,400 |
416,736 |
0 |
| Cvijic Christine Mikail | President and CFO |
May 06 '26 |
Sale |
31.25 |
9,600 |
300,043 |
93,640 |
| McMinn Rachel | Chief Executive Officer |
Mar 26 '26 |
Sale |
22.07 |
3,352 |
73,995 |
1,344,307 |
| Jordan Julie | Chief Medical Officer |
Mar 26 '26 |
Sale |
21.89 |
828 |
18,128 |
12,472 |
| Cvijic Christine Mikail | President and CFO |
Mar 26 '26 |
Sale |
21.62 |
2,558 |
55,316 |
103,240 |
| Cvijic Christine Mikail | President and CFO |
Mar 13 '26 |
Sale |
20.81 |
4,045 |
84,176 |
105,798 |
4.22%
자본화:
|
볼륨(24시간):